Older adults who followed a coached lifestyle program showed measurable protection against age-related cognitive decline compared with those who managed the same habits on their own, according to results from the U.S. POINTER trial and its Latin American replication presented at the Alzheimer's Association International Conference in London in July 2026.
The program targets four aspects of daily life shown to influence brain aging: regular physical activity, a brain-healthy diet, cognitive and social engagement, and monitoring of heart health markers such as blood pressure, cholesterol, and blood sugar. That combination protected global cognition for up to two years in adults already flagged as being at elevated risk for Alzheimer's disease.
What "at risk" actually means
The U.S. POINTER trial enrolled 2,111 adults ages 60 to 79 across five sites, and eligibility hinged on a stack of everyday risk factors rather than a diagnosis. Participants had to be sedentary, eat a suboptimal diet, and carry cardiometabolic concerns such as high blood pressure, cholesterol, or blood sugar, and 78 percent also reported a first-degree family history of memory loss, according to the AAIC 2025 results release.
The mean age was 68, roughly seven in ten participants were women, and about 30 percent were carriers of the APOE-e4 gene variant tied to higher Alzheimer's risk. Cognition was normal at the start.
Also read: A blood test may now predict your Alzheimer's risk a full decade before symptoms
What the program looked like
The structured arm was intensive. Participants aimed for 30 to 35 minutes of moderate-to-vigorous aerobic activity four times a week, added strength and flexibility training twice a week, followed the MIND diet emphasizing leafy greens, berries, nuts, whole grains, olive oil, and fish, completed computer-based brain training three times a week, and had regular check-ins on blood pressure, weight, and lab values.
Peer group meetings and coaching kept people on the plan, adding a layer of mental and social activity that research links to a lower dementia risk. After nearly two years, the structured group improved on the global cognition score by 0.029 standard deviations per year more than the self-guided group, with the largest gains in executive function.
Replicated across 11 Latin American countries
The Latin American version, LatAm-FINGERS, was published in The Lancet on July 13, 2026 and enrolled 1,065 adults ages 60 to 77 at 12 sites in Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, the Dominican Republic, Ecuador, Mexico, Peru, and Uruguay. Salsa and tango replaced treadmill sessions where useful, and avocado and quinoa carried the nutrition plan.
Participants in the coached group showed 55 percent greater improvement in overall memory, thinking, and reasoning than the self-guided group over two years, according to the AAIC 2026 release. Episodic memory, executive function, and processing speed all moved in the same direction. Eighty-two percent of participants completed the full two years, and no serious adverse events were tied to the intervention.
Also read: A daily vitamin D supplement may cut your risk of autoimmune disease by over 20%
"We now have a second strong finding in a completely different part of the world, which suggests that the U.S. POINTER formula can be adapted for anybody," said Laura D. Baker, Ph.D., professor at Wake Forest University and principal investigator of U.S. POINTER.
The next frontier: lifestyle plus a GLP-1 drug
At AAIC 2026 the Alzheimer's Association also launched PROTECT-Cog, a global three-year trial that pairs the POINTER lifestyle program with a GLP-1 receptor agonist, the same drug class as semaglutide, the active ingredient in Novo Nordisk's Ozempic and Wegovy. The $100 million study will test whether adding the metabolism-targeting drug amplifies the cognitive benefit of the lifestyle program in older adults at risk of decline, with evaluations every six months.
The trial builds on real-world healthcare data suggesting GLP-1 medicines may reduce dementia risk by 40 to 70 percent compared with other diabetes drugs, though those signals come from observational records rather than randomized trials.
For readers already worried about memory changes, the practical message from POINTER is narrower than a cure. The program did not reverse cognitive decline or prevent Alzheimer's disease, and researchers stress that individual results will vary. Anyone with new memory concerns or a strong family history should raise it with a doctor before starting a structured program.
Also read: Combining cardio and strength training could cut your diabetes risk by half
Also read: Your cholesterol levels by age: what's normal for LDL, HDL and more
This article is made and published by Jesper Bengtson, who may have used AI in the preparation.